{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:34:59Z","timestamp":1788950099875,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The continuing spread of tuberculosis (TB) worldwide, especially drug-resistant TB, poses a major challenge to healthcare systems globally. Addressing this requires appraising the cost effectiveness of existing pharmacological interventions against TB to identify key drivers of cost effectiveness and value and guide pharmaceutical innovation and novel drug regimen development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Studies were identified from a search of six database: MEDLINE MEDLINE-In Process, MEDLINE Epub Ahead of Print, EMBASE, Cochrane Database of Systematic Reviews, and Econlit in July 2022. Two reviewers independently assessed all identified studies and reports using pre-defined inclusion\/exclusion criteria. Study methodological quality was assessed, data were extracted in standard tables, and results were narratively synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 991 studies and 53 HTA reports were identified with 20 studies and 3 HTA reports meeting the inclusion criteria. Quality assessment of the 20 studies identified 4 with minor limitations, while the remainder were assessed as having potentially or very serious limitations. Sixteen studies conducted cost-utility analyses, 6 conducted cost-effectiveness analyses, and 2 conducted cost-comparison analyses with some studies performing multiple analyses. The majority (n\u2009=\u200916) were model-based. Eleven studies analyzed the cost-effectiveness of bedaquiline, 6 compared shorter to longer\/standard duration regimens, 2 assessed ethambutol, and 1 assessed delamanid. Key drivers of cost effectiveness were drug costs, the number of TB cases, the portion of cases with sputum culture conversion, treatment delivery costs, and treatment efficacy. Common value elements considered included adverse events, drug resistance, and improving treatment adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that out of the pharmacological treatments assessed, bedaquiline is likely a cost-effective addition to existing treatment regimens\/background treatment regimens, while ethambutol is not likely to be. Newer shorter regimens, even if more costly, seem to be more cost-effective compared to longer regimens. These results illustrate the limited number of novel cost-effective pharmacological interventions and highlight a need to develop new drugs\/regimens against TB to overcome resistance, taking into account the key drivers of cost effectiveness and other value attributes identified from this review.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2024.1201512","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T12:06:46Z","timestamp":1713269206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A systematic review of economic evaluations of pharmacological treatments for active tuberculosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Sarosh","family":"Nagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","volume-title":"Global tuberculosis report 2019","year":"2019"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"151951","DOI":"10.1016\/j.imbio.2020.151951","article-title":"Natural and trained innate immunity against Mycobacterium tuberculosis","volume":"225","author":"Ferluga","year":"2020","journal-title":"Immunobiology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3208\/arztebl.2019.0729","article-title":"The diagnosis and treatment of tuberculosis","volume":"116","author":"Su\u00e1rez","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.332.7551.1194","article-title":"Pulmonary tuberculosis: diagnosis and treatment","volume":"332","author":"Campbell","year":"2006","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3181\/00379727-57-14769","article-title":"Effect of streptomycin and other antibiotic substances upon mycobacterium tuberculosis and related organisms","volume":"57","author":"Schatz","year":"1944","journal-title":"Exp. Biol. Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1128\/AAC.46.2.267-274.2002","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective","volume":"46","author":"Gillespie","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12088-017-0674-0","article-title":"Bedaquiline: fallible Hope against drug resistant tuberculosis","volume":"57","author":"Singh","year":"2017","journal-title":"Indian J Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1016\/S2213-2600(21)00496-3","article-title":"Global tuberculosis progress reversed by COVID-19 pandemic","volume":"9","author":"Kirby","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref12","year":"2022"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40258-015-0183-4","article-title":"A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection","volume":"13","author":"Campbell","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"130976","DOI":"10.1155\/2011\/130976","article-title":"A systematic review of economic evaluations of chemoprophylaxis for tuberculosis","volume":"2011","author":"Chavan","year":"2011","journal-title":"J Trop Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"736986","DOI":"10.3389\/fphar.2021.736986","article-title":"A systematic review of economic evaluations of active tuberculosis treatments","volume":"12","author":"Byun","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jval.2022.01.001","article-title":"Diagnostics and treatments of COVID-19: a living systematic review of economic evaluations","volume":"25","author":"Elvidge","year":"2022","journal-title":"Value Health"},{"key":"ref17","year":"2016"},{"key":"ref18","year":""},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e39187","DOI":"10.1371\/journal.pone.0039187","article-title":"Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis","volume":"7","author":"Manabe","year":"2012","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1183\/09031936.00005613","article-title":"Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance","volume":"43","author":"Law","year":"2014","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5588\/ijtld.12.0776","article-title":"Cost-effectiveness of novel first-line treatment regimens for tuberculosis","volume":"17","author":"Owens","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0120763","DOI":"10.1371\/journal.pone.0120763","article-title":"Cost-effectiveness of adding Bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK","volume":"10","author":"Wolfson","year":"2015","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e0145796","DOI":"10.1371\/journal.pone.0145796","article-title":"The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa","volume":"10","author":"Knight","year":"2015","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.rmed.2015.01.017","article-title":"Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba\u2122 to background regimens in Germany","volume":"109","author":"Diel","year":"2015","journal-title":"Respir Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.clinthera.2016.01.020","article-title":"Cost-effectiveness of Bedaquiline for the treatment of multidrug-resistant tuberculosis in the Republic of Korea","volume":"38","author":"Park","year":"2016","journal-title":"Clin Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1186\/s12879-016-2064-3","article-title":"Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis","volume":"16","author":"Gomez","year":"2016","journal-title":"BMC Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1283105","DOI":"10.1080\/20016689.2017.1283105","article-title":"Cost-effectiveness of Bedaquiline in MDR and XDR tuberculosis in Italy","volume":"5","author":"Codecasa","year":"2017","journal-title":"J Mark Access Health Policy"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12913-016-1931-3","article-title":"Health outcomes of Bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries","volume":"17","author":"Lu","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40258-017-0352-8","article-title":"Incremental cost effectiveness of Bedaquiline for the treatment of rifampicin-resistant tuberculosis in South Africa: model-based analysis","volume":"16","author":"Schnippel","year":"","journal-title":"Appl Health Econ Health Policy"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.5588\/ijtld.17.0869","article-title":"Impact of adverse drug reactions on the incremental cost-effectiveness of Bedaquiline for drug-resistant tuberculosis","volume":"22","author":"Schnippel","year":"","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12913-017-2118-2","article-title":"Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany","volume":"17","author":"Wirth","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijid.2018.10.007","article-title":"Cost-effectiveness of Bedaquiline or Delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden City of China","volume":"78","author":"Fan","year":"2019","journal-title":"Int J Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jinf.2019.09.006","article-title":"A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK","volume":"80","author":"Manalan","year":"2020","journal-title":"J Infect"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14787210.2020.1742109","article-title":"The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa","volume":"18","author":"Mpobela Agnarson","year":"2020","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2471\/BLT.19.243584","article-title":"Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial","volume":"98","author":"Madan","year":"2020","journal-title":"Bull World Health Organ"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1513\/AnnalsATS.201905-418OC","article-title":"Shortened tuberculosis treatment for people with HIV in South Africa. A model-based evaluation and cost-effectiveness analysis","volume":"17","author":"Reddy","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e0241065","DOI":"10.1371\/journal.pone.0241065","article-title":"Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant\/multi-drug resistant tuberculosis in Nigeria","volume":"15","author":"Bada","year":"2020","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e051521","DOI":"10.1136\/bmjopen-2021-051521","article-title":"Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines","volume":"11","author":"Gomez","year":"2021","journal-title":"BMJ Open"},{"key":"ref39","year":"2012"},{"key":"ref40","author":"Bundesausschuss","year":"2020"},{"key":"ref41","volume-title":"All Wales medicines strategy group","year":"2015"},{"key":"ref42","year":"2018"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/bab.2052","article-title":"Metformin and rifampicin combination augments active to latent tuberculosis conversion: a computational study","volume":"68","author":"Yadav","year":"2021","journal-title":"Biotechnol Appl Biochem"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1056\/NEJMc2103049","article-title":"Bedaquiline-resistant tuberculosis associated with Rv0678 mutations","volume":"386","author":"Omar","year":"2022","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4102\/sajid.v35i1.20","article-title":"Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis","volume":"35","author":"Gaida","year":"2020","journal-title":"S Afr J Infect Dis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","article-title":"Bedaquiline: current status and future perspectives","volume":"25","author":"Khoshnood","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1201512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T12:06:54Z","timestamp":1713269214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1201512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":46,"alternative-id":["10.3389\/fpubh.2024.1201512"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1201512","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"article-number":"1201512"}}